에 대한 최신 뉴스 Senseonics Holdings (AMEX:SENS) 주식

Senseonics Holdings

Senseonics Holdings Inc is a medical technology company. It is focused on the design, development, and commercialization of glucose monitoring system, which helps people to manage their diabetes community with differentiated, long-term implantable glucose management technology. Its products and services include a Continuous glucose monitoring system, Sensor, Smart transmitter, and Mobile app. The firm has a Glucose monitoring product segment. The majority of the revenue is generated outside of the United States.

Senseonics Holdings Inc

SENSO

SENSHU ELECTRIC CO LTD by SENSHU ELECTRIC CO LTD.

SENSHU IKEDA HLDGS INC by Senshu Ikeda Holdings Inc.

SENSIO TECHNOLOGIES INC by SENSIO Technologies Inc.

SENSYNE HEALTH LTD by Sensyne Health Ltd.

SENSEN NETWORKS LTD by SenSen Networks Limited

SenSen Networks Ltd

SENSASURE TECHNOLGIES INC by SensaSure Technologies, Inc.

Sensasure Technologies Inc

Sensata Technologies Holding plc Ordinary Shares

Sensata Technologies Holding PLC

SENSE TECHS INC ORD by Sense Technologies, Inc.

Sense Technologies Inc

SENSETIME GRP INC CL B by SENSETIME GROUP INC.

SenseTime Group Inc

Sensei Biotherapeutics, Inc. - Common Stock

Sensei Biotherapeutics Inc

SENSIBLE MEATS INC by SENSIBLE MEATS INC.

Sensible Meats Inc

Sensient Technologies Corporation Common Stock

Sensient Technologies Corp

Senstar Technologies Corporation - Common Shares

Senstar Technologies Corp

Sensus Healthcare Inc

NANO Nuclear Energy Inc. (NASDAQ:<a href="https://www.benzinga.com/stock/NNE#NASDAQ">NNE</a>) ("NANO Nuclear" or "the Company"), a leading advanced nuclear energy and technology company focused on developing clean energy solutions, today announced that on Thursday, April 24, 2025, a Las Vegas judge granted in full two motions to dismiss brought by NANO Nuclear Energy Inc. and its officers and directors in a putative shareholder derivative action entitled Latza v. Walker, et al., Case No. A-24-900423-B, Clark County, Nevada District Court.
"We are extremely pleased that this case has been so promptly adjudicated and dismissed in its entirety," said Jay Yu, Founder and Chairman of NANO Nuclear. "This ruling will allow us to devote more of our time and attention to NANO Nuclear's primary mission of becoming the leading commercially focused advanced nuclear energy technology company in America. We thank our legal team at Ellenoff Grossman &amp; Schole for their insight and hard work in achieving this result."

News

Legal

Judge Tosses Case Against NANO Nuclear Leaders, Company Refocuses on Advanced Nuclear Tech Growth

Ascendiant Capital analyst Edward Woo maintains RenovoRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNXT#NASDAQ">RNXT</a>) with a Buy and raises the price target from $9 to $11.

Price Target

Analyst Ratings

RNXT

Ascendiant Capital Maintains Buy on RenovoRx, Raises Price Target to $11

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the<a href="https://www.benzinga.com/topic/rsi"> RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">UnitedHealth Group Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>)</h3>
<ul>
<li>On April 21, UnitedHealth reported worse-than-expected first-quarter results and cut its FY25 adjusted EPS guidance below estimates. "UnitedHealth Group grew to serve more people more comprehensively but did not perform up to our expectations, and we are aggressively addressing those challenges to position us well for the years ahead, and return to our long-term earnings growth rate target of 13 to 16%," said Andrew Witty, CEO of UnitedHealth. The company's stock fell around 19% over the past month and has a 52-week low of $412.02.</li>
<li>RSI Value: 27.1</li>
<li>UNH Price Action: Shares of UnitedHealth fell 1.3% to close at $418.64 on Friday.</li>
<li>Edge Stock Ratings: 26.37 Momentum score with Value at 69.10. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/quote/UNH"><img loading="lazy" decoding="async" width="481" height="192" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28070358/image-186.png" alt="" class="wp-image-890598" style="width:331px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28070358/image-186.png 481w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28070358/image-186-300x120.png 300w" sizes="(max-width: 481px) 100vw, 481px" /></a></figure>
<h3 class="wp-block-heading">Bristol-Myers Squibb Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>)&nbsp;&nbsp;</h3>
<ul>
<li>On April 24, Bristol Myers Squibb reported first-quarter 2025 revenues of $11.20 billion, beating the consensus of $10.70 billion. &#8220;Our strong execution in the first quarter drove continued momentum across our Growth Portfolio and meaningful progress in the pipeline,&#8221; said Christopher Boerner, Ph.D., board chair and chief executive officer, Bristol Myers Squibb. The company's stock fell around 20% over the past month and<a href="https://www.benzinga.com/quote/BMY"> has a 52-week low</a> of $39.35.</li>
<li>RSI Value: 25</li>
<li>BMY Price Action: Shares of Bristol-Myers Squibb dipped 1.6% to close at $47.90 on Friday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the trend in <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0428">BMY stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0428"><img loading="lazy" decoding="async" width="916" height="847" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28071255/image-187.png" alt="" class="wp-image-890615" style="width:544px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28071255/image-187.png 916w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28071255/image-187-300x277.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28071255/image-187-768x710.png 768w" sizes="(max-width: 916px) 100vw, 916px" /></a></figure>
<h3 class="wp-block-heading">X4 Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XFOR#NASDAQ">XFOR</a>)</h3>
<ul>
<li>On April 24, X4 Pharmaceuticals company announced a 1-for-30 reverse stock split. The company has a 52-week <a href="https://www.benzinga.com/quote/XFOR">low of $0.17.</a></li>
<li>RSI Value: 14.7</li>
<li>XFOR Price Action: Shares of X4 Pharmaceuticals closed at $5.70 on Friday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential breakout in <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0428">XFOR shares</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0428"><img loading="lazy" decoding="async" width="876" height="841" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28071347/image-188.png" alt="" class="wp-image-890619" style="width:566px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28071347/image-188.png 876w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28071347/image-188-300x288.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28071347/image-188-768x737.png 768w" sizes="(max-width: 876px) 100vw, 876px" /></a></figure>
Learn more about BZ Edge Rankings—click to see scores for other stocks in the sector and s<a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">ee how they compare.</a> 
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/04/45007044/wall-streets-most-accurate-analysts-give-their-take-on-3-real-estate-stocks-delivering-high-dividend-yields-5">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Real Estate Stocks Delivering High-Dividend Yields</a> </li>
</ul>
Photo via Shutterstock

Long Ideas

Pre-Market Outlook

Markets

Trading Ideas

XFOR

Top 3 Health Care Stocks That May Rocket Higher In April

In connection with its name change, the Company also plans to change its ticker symbol for the Barrick common shares listed on the New York Stock Exchange from ‘GOLD' to ‘B', to become effective at the start of trading on May 9, 2025. The Barrick common shares will continue to trade under the ‘ABX' ticker symbol on the Toronto Stock Exchange. The new CUSIP number for the Barrick common shares effective at the start of trading on May 9, 2025 will be 06849F108.

GOLD

Barrick Gold Plans To Rebrand As Barrick Mining Corporation And Change NYSE Ticker To 'B'

Barclays analyst Paul Kearney initiates coverage on Macy's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/M#NYSE">M</a>) with a Equal-Weight rating and announces Price Target of $12.

Initiation

Barclays Initiates Coverage On Macy's with Equal-Weight Rating, Announces Price Target of $12

Needham analyst James Ricchiuti maintains Bel Fuse (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BELFB#NASDAQ">BELFB</a>) with a Buy and lowers the price target from $100 to $95.

BELFB

Needham Maintains Buy on Bel Fuse, Lowers Price Target to $95

Acquisition Supports Company's Growth in Innovative Lifestyle Offerings
BETHESDA, Md., April 28, 2025 /PRNewswire/ -- Today, Marriott International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAR#NASDAQ">MAR</a>) announced it has reached an agreement to acquire the lifestyle brand <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4414142-1&amp;h=2489686303&amp;u=https%3A%2F%2Fwww.citizenm.com%2F&amp;a=citizenM">citizenM</a>, a unique and innovative offering in the select-service segment. The transaction is expected to accelerate Marriott's global expansion of its select-service and lifestyle lodging offerings, as the company continues to focus on expanding its portfolio to provide even more exciting options for guests and Marriott Bonvoy members around the world.
At closing of the transaction, Marriott will pay $355 million to acquire the brand and related intellectual property. Following closing, the citizenM portfolio will become part of Marriott's system, with the hotels owned and leased by the seller subject to new long-term franchise agreements with Marriott. Stabilized fees for the open and under construction pipeline portfolio are anticipated to be approximately $30 million annually. The seller may also receive earn-out payments up to $110 million that are based on the future growth of the brand over a specified, multi-year timeframe. These payments would not begin until the fourth year following closing.
 &nbsp;

Marriott International Agrees To Acquire citizenM And Its Intellectual Property In $355M Deal

Barclays analyst Paul Kearney initiates coverage on Gildan Activewear (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GIL#NYSE">GIL</a>) with a Overweight rating and announces Price Target of $51.

Barclays Initiates Coverage On Gildan Activewear with Overweight Rating, Announces Price Target of $51

CSTL

Castle Biosciences Surpasses 200,000 DecisionDx-Melanoma Clinical Test Orders

The ongoing dispute in Louisiana over who should bear the cost of new power plants required for&nbsp;Meta Platforms Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) $10 billion data center is heating up.
What Happened: The Louisiana Public Service Commission received new testimony on April 11 from consumer advocates and climate groups. They urged the state regulator to reject a proposal by Meta&#8217;s electricity provider, Entergy Louisiana, to pass on $5 billion in construction costs for the plants to its entire customer base, <a href="https://www.businessinsider.com/meta-data-center-louisiana-5b-ratepayers-2025-4">reported</a> Business Insider on Saturday.
Entergy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETR#NYSE">ETR</a>) has put forward a proposal to construct three new natural gas power plants to support Meta&#8217;s data centers. The utility contends that the data center could have a significant impact on the state, potentially creating 300 to 500 jobs with an average salary of $82,000.
However, advocates and climate groups argued that Entergy&#8217;s 1.1 million electric customers should not bear the cost of Meta&#8217;s power usage. Cathy Kunkel, an energy consultant, also cautioned that the utility&#8217;s plan could &#8220;put other ratepayers at risk of having to absorb hundreds of millions, if not billions of dollars, of additional costs&#8221; tied to Meta&#8217;s data center.
Even Walmart (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>) in Louisiana has raised concerns, seeking a guarantee that Meta&#8217;s increasing power demand will not affect it or other Entergy customers in the state.
SEE ALSO:&nbsp;<a href="https://benzinga.com/markets/cryptocurrency/25/04/45003759/arks-bitcoin-bear-case-is-300000-by-2030-whats-the-bull-case" target="_blank" rel="noreferrer noopener">ARK&#8217;s Bitcoin &#8216;Bear Case&#8217; Is $300,000 By 2030—What&#8217;s The Bull Case? &#8211; Benzinga</a>
Why It Matters: &nbsp;The controversy surrounding the funding of Meta&#8217;s data center highlights the broader issue of who should bear the cost of tech companies&#8217; increasing power consumption. As these companies continue to expand their data centers, the demand for electricity is likely to rise, potentially leading to higher costs for consumers.&nbsp;
These concerns stem from the fact that Meta&#8217;s power requirements have grown since the company <a href="https://www.benzinga.com/24/12/42337936/meta-unveils-10-billion-ai-data-center-in-louisiana-a-game-changer-for-tech-and-jobs">first revealed </a>its intention to construct an AI data center in Louisiana, which has contributed to higher service costs for Entergy. The precise amount of additional electricity Meta is requesting remains unclear, as the relevant details have been redacted from the filings.
This situation is further complicated by the reports of recent pullout of Amazon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) and Microsoft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) from data center leases, raising questions about the sustainability of the AI development boom.&nbsp;However, Nvidia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) and Amazon have recently <a href="https://www.benzinga.com/25/04/45001873/amazon-and-nvidia-dismiss-fears-of-ai-data-center-pullback-we-continue-to-see-very-strong-demand">denied reports</a> of slowdown in AI data center construction. 
The momentum rating of META is 75.93% while its growth rating is 75%, according to&nbsp;<a href="https://www.benzinga.com/quote/META" target="_blank" rel="noreferrer noopener">Benzinga&#8217;s Proprietary Edge Rankings</a>. For an in-depth report on more stocks and insights into growth opportunities,&nbsp;<a href="https://www.benzinga.com/screener/top-momentum-stocks" target="_blank" rel="noreferrer noopener">sign</a>&nbsp;<a href="https://www.benzinga.com/screener/top-momentum-stocks" target="_blank" rel="noreferrer noopener">up for Benzinga Edge.</a>
<ul>
<li>READ MORE:&nbsp;<a href="https://benzinga.com/25/04/45031932/donald-trump-says-democrats-did-everything-possible-to-destroy-christopher-columbus-vows-to-restore-his-statues-and-reputation" target="_blank" rel="noreferrer noopener">Trump Vows To Bring Back Columbus Day &#8216;From The Ashes,&#8217; Promises To Restore &#8216;Same Rules, Dates And Locations&#8217; &#8211; Benzinga</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Tech

AMZN

MSFT

NVDA

Meta's Louisiana Data Center Sparks Debate Over Who Should Foot The $5 Billion Power Bill: '...Put Other Ratepayers At Risk Of Having To Absorb Hundreds Of Millions,' Says Expert

<ul>
<li>Oral presentation shows ADCT-242 targeting Claudin-6 was well-tolerated and demonstrated potent antitumor activity in ovarian and non-small lung cancer</li>
<li>Poster presentations highlight&nbsp;antitumor activity and safety of novel PSMA-targeted and ASCT2- targeted ADCs</li>
</ul>

ADCT

ADC Therapeutics' Claudin-6 Targeting ADC Shows Strong Single-Agent And Combination Potential In Solid Tumors

Data presented at the American Association for Cancer Research (AACR) Annual Meeting 2025Dose Finding completed with no dose limiting toxicities and preliminary recommended Phase 2 dose (RP2D) identified5 of 7 best
Data presented at the American Association for Cancer Research (AACR) Annual Meeting 2025
Dose Finding completed with no dose limiting toxicities and preliminary recommended Phase 2 dose (RP2D) identified
5 of 7 best overall response evaluable patients achieved ORR (3 CR, 1 CRh and 1 morphologic leukemia-free state) across all dose cohorts, including 1 CR and 1 CRh in 3 patients in preliminary RP2D cohort
4 of 4 cCR patients were measurable residual disease (MRD) negative as assessed by local standard of care
Early deep responses with SENTI-202 noted across dose levels with all cCRs ongoing as of the data cut and longest durability of 8+ months
Company to host webcast to discuss the new Phase 1 SENTI-202 data today, April 28th at 8:30 AM ET; <a href="https://www.globenewswire.com/Tracker?data=AbxbR4ScrJ0izIo4Ac5VlxUHBOddH6gJTQ2V2yuu38djGt54HInP6iB0FrHdAu9eXGkLs1e8BNnHuvPkTAM4eOUtRU2gn8tsGBJHwLH2M9IHHXKIVb64CkWt6SNdqkU3YpZRIiFL8WAtnhDFJCBK_Q==">Register Here</a>
Announces certain preliminary first quarter 2025 financial results and provides pipeline update
SOUTH SAN FRANCISCO, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNTI#NASDAQ">SNTI</a>) ("Senti Bio" or the "Company"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today reported additional positive preliminary data from a Phase 1 clinical trial of SENTI-202, a potential first-in-class off-the-shelf Logic Gated selective CD33 OR FLT3 NOT EMCN chimeric antigen receptor natural killer (CAR-NK) investigational cell therapy, for the treatment of relapsed/refractory (R/R) hematologic malignancies including acute myeloid leukemia ("AML"). As previously announced, the Company will host a <a href="https://www.globenewswire.com/Tracker?data=qnw9Be6du1Qo9doPNbJ7zdSPx5_1n2-DBTj98Jvxm8KeXiH6VyCDkvCbYRzXMVdCFNOvd1qv77SNVc4uIGAQqbLYB9d08aZoFAghd0w6_xgQbaly1JA0Tig5i-FyAJbfcSHd68iJmdd6ogneh-V6gUyBY3KKv7SStlNlv0XiHZo=">conference call and webcast</a> to discuss the presented data today, April 28, 2025, at 8:30 AM ET (details below).

SNTI

Senti Biosciences Reports Additional Preliminary Data From Phase 1 Clinical Trial Of SENTI-202 For R/R Hematologic Malignancies Including AML

Initial real-world data from nearly 40,000 EYLEA HD patients will provide early insights on effectiveness of EYLEA HD in everyday clinical practice
New indirect comparisons will evaluate EYLEA HD and faricimab on measures of efficacy, dosing frequency and potential economic benefits in patients with wet age-related macular degeneration and diabetic macular edema
&nbsp;Regeneron Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) today announced the upcoming presentation of 27 abstracts, including eight oral presentations on EYLEA HD&#xAE; (aflibercept) Injection 8 mg in wet age-related macular degeneration (wAMD), diabetic macular edema (DME) and diabetic retinopathy (DR). Among the new results and analyses are initial insights on the real-world use of EYLEA HD in clinical practice, which reinforce the outcomes seen in pivotal trials. These data will be presented at the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting from May 4 to 8 in Salt Lake City.
"Our data presentations at ARVO reflect the robust and rapidly growing body of evidence that support the use of EYLEA HD becoming the new standard of care for people living with wet age-related macular degeneration, diabetic macular edema and diabetic retinopathy," said Boaz Hirshberg, M.D., Senior Vice President, Clinical Development, Internal Medicine at Regeneron. "This includes new analyses examining the initial real-world experiences of nearly 40,000 patients treated with EYLEA HD showing, in everyday clinical practice, a positive impact through improved vision and longer dosing intervals for patients. Although early, these data reinforce the value EYLEA HD is bringing to patients with serious retinal diseases."
Notable new presentations at ARVO include:
<ul>
<li>Four analyses evaluating initial real-world experiences with EYLEA HD among patients with wAMD or DME, including both those who were previously naive to treatment and those who switched from other anti-vascular endothelial growth factor (VEGF) therapies</li>
<li>A network meta-analysis indirectly comparing the efficacy and number of injections received for EYLEA HD and faricimab in patients with DME or wAMD, based on the longest follow-up data from Phase 3 clinical trials</li>
<li>A modeling analysis of the potential economic benefit of EYLEA HD compared to faricimab for the treatment of patients with wAMD or DME in the U.S. over three years &nbsp;</li>
</ul>
The most common adverse reactions (≥3%) reported in patients treated with EYLEA&nbsp;HD were cataract, conjunctival hemorrhage, intraocular pressure increased, ocular discomfort/eye pain/eye irritation, vision blurred, vitreous floaters,&nbsp;vitreous detachment, corneal epithelium defect and retinal hemorrhage.&nbsp;

Biotech

General

REGN

Regeneron Pharmaceuticals Announces The Upcoming Presentation Of 27 Abstracts, Including Eight Oral Presentations On EYLEA HD Injection 8 MG . Data Will Be Presented at the Association For Research In Vision and Ophthalmology 2025 Annual Meeting May 4 To 8 in Salt Lake City, Utah

These poster presentations feature five of the company's drug candidates: novel tyrosine kinase inhibitor (TKI) olverembatinib (HQP1351), Bcl-2 inhibitor lisaftoclax (APG-2575), FAK/ALK/ROS1 TKI APG-2449, embryonic ectoderm development (EED) inhibitor APG-5918, and IAP antagonist AS03157.

Health Care

AAPG

Ascentage Pharma Presented Results From Five Preclinical Studies During Poster Presentations At The 2025 American Association For Cancer Research Annual Meeting

QuickLogic Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QUIK#NASDAQ">QUIK</a>), a leading developer of embedded FPGA (eFPGA) Hard IP and User Tools, ruggedized FPGAs, and Endpoint AI/ML solutions, announced today the delivery of eFPGA Hard IP optimized for Intel 18A technology to a customer that selected QuickLogic's IP for its Test Chip. This milestone marks the first time eFPGA Hard IP has been delivered for a sub-5nm process node and is expected to set new standards for low power consumption, high performance, and optimal silicon area utilization (PPA).
&nbsp;
By leveraging the power of its proprietary Australis&#x2122; IP Generator, QuickLogic established the first <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4413955-1&amp;h=2637068950&amp;u=https%3A%2F%2Fwww.quicklogic.com%2Fefpga-ip%2F&amp;a=eFPGA+Hard+IP">eFPGA Hard IP</a> for Intel 18A in only six months. With foundry-specific Hard IP now completed, customer-specific variants can be delivered even faster. QuickLogic eFPGA Hard IP is supported by two versions of its FPGA User Tools; Aurora, which is comprised of 100% Open-Source components that give designers complete transparency and inspectability, and Aurora Pro, which includes Synopsys&#xAE; Synplify&#xAE; FPGA Logic Synthesis.

INTC

QUIK

QuickLogic Delivers First eFPGA Hard IP for Intel 18A, Setting New Standard for Low Power and High Performance

RDHL

RedHill Biopharma Announces The China National Intellectual Property Administration Formally Allowed A Critical Use Of Composition-Of-Matter Patent For RHB-107, A Potential COVID-19 Treatment

Opera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRA#NASDAQ">OPRA</a>) sees Q2 sales of $134.000 million-$138.000 million vs $134.12 million analyst estimate.

Guidance

OPRA

Opera Sees Q2 Sales $134.000M-$138.000M vs $134.12M Est

<ul>
<li>Approval-in-Principle Received For Up To $900,000 in Government Funding to&nbsp;</li>
<li>Directly Support Globavend's Expansion into the China Market</li>
</ul>

Globavend Gains Government Approval To Expand Into China, Securing Potential $900,000 Non-Dilutive Grant

VYJUVEK approved for the treatment of DEB from birth in Europe
Approval allows for dosing at home or in a healthcare setting, as well as patient or caregiver administration if deemed appropriate by a healthcare professional
PITTSBURGH, April 28, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRYS#NASDAQ">KRYS</a>) announced today that on April 23, 2025, the European Commission (EC) granted marketing authorization to VYJUVEK&#xAE; (beremagene geperpavec-svdt) for the treatment of wounds in patients with dystrophic epidermolysis bullosa (DEB) who have mutations in the collagen type VII alpha 1 chain (COL7A1) gene, starting from birth. VYJUVEK is designed to address the genetic root cause of DEB by delivering functional copies of the human COL7A1 gene to provide wound healing and sustained functional type VII collagen protein expression with redosing. VYJUVEK is the first corrective medicine approved in Europe for the treatment of DEB. The approval granted by the EC allows for flexible VYJUVEK dosing either at home or in healthcare setting, with the option for patient or caregiver administration if deemed appropriate by a healthcare professional.
This EC decision authorizes the marketing of VYJUVEK in all European Union member states, as well as Iceland, Norway and Liechtenstein. The timing for availability of VYJUVEK in individual countries will depend on multiple factors, including the completion of reimbursement procedures. The Company is planning for its first European launch in Germany in mid-2025.

KRYS

EC Grants Marketing Authorization To Krystal Biotech's VYJUVEK For Treatment Of Wounds In Patients With DEB Who Have Mutations In COL7A1 Gene, Starting From Birth

Opera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRA#NASDAQ">OPRA</a>) raises FY2025 sales outlook from $555.00 million-$570.00 million to $567.00 million-$582.00 million vs $565.46 million estimate.

Opera Raises FY2025 Sales Guidance from $555.00M-$570.00M to $567.00M-$582.00M vs $565.46M Est

Press Releases

Senseonics Holdings, Inc. Announces $16 Million Registered Direct Offering

Earnings

Senseonics Holdings, Inc. Reports Third Quarter 2024 Financial Results

Senseonics Holdings, Inc. to Participate in Upcoming Investor Conferences

Senseonics Holdings, Inc. Provides Update on Eversense 365 Launch

Senseonics Holdings, Inc. Announces Business Updates Including Preliminary 2024 Results, 365 Launch Update and Cancellation of Special Meeting

Senseonics Completes CE Mark Submission for Eversense 365, World's Longest-lasting Continuous Glucose Monitor

Senseonics Holdings, Inc. Schedules Fourth Quarter and Full Year 2024 Earnings Release and Conference Call for March 3, 2025 at 4:30 P.M. Eastern Time

Senseonics Holdings, Inc. to Participate in the TD Cowen 45th Annual Health Care Conference

Eversense 365 and SweetSpot Integrate Software to Optimize Diabetes Care

Senseonics Holdings, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results

SENS

AngioDynamics

Artivion

Axogen

Beta Bionics

Butterfly Network, Inc. Class A Common Stock

Butterfly Network

CeriBell

ClearPoint Neuro

Delcath Systems

Integra LifeSciences Holdings Corporation - Common Stock

Integra Lifesciences

iRadimed

Kestra Medical Technologies, Ltd. - Common Stock

Kestra Medical Techs

NeuroPace

Orthofix Medical

Omnicell

Pulse Biosciences

SI-BONE

Semler Scientific

SANUWAVE Health

Surmodics

Neuronetics

Tactile Systems Technology, Inc. - Common Stock

Tactile Systems Tech

Treace Medical Concepts, Inc. - Common Stock

Treace Medical Concepts

Tandem Diabetes Care, Inc. - Common Stock

Comments

Senseonics Holdings

뉴스

에 대한 최신 뉴스 Senseonics Holdings (AMEX:SENS) 주식

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌